Baidu
map

CID:高HBV水平可导致急性乙型肝炎发展为慢性感染

2013-06-06 CID dxy

某些急性乙型肝炎病毒(HBV)感染患者会发展为慢性感染。然而,目前尚未建立相关的方法来鉴别这类患者以实现优化管理。因此,来自东京大学医学研究生院的医学博士Hiroshi Yotsuyanagi等人展开一项研究,研究结果在线发表于2013年5月23日的Clinical Infectious Diseases(《临床感染疾病》)杂志上。作者发现,只有那些无法在12个月内清除HBV的急性乙型肝炎患者才有

某些急性乙型肝炎病毒(HBV)感染患者会发展为慢性感染。然而,目前尚未建立相关的方法来鉴别这类患者以实现优化管理。因此,来自东京大学医学研究生院的医学博士Hiroshi Yotsuyanagi等人展开一项研究,研究结果在线发表于2013年5月23日的Clinical Infectious Diseases(《临床感染疾病》)杂志上。作者发现,只有那些无法在12个月内清除HBV的急性乙型肝炎患者才有可能最终发展为慢性感染。

研究人员共随访了日本的215例急性乙型肝炎患者,直至其HBsAg(乙型肝炎病毒表面抗原)清除或发展为慢性感染。从一开始就连续监测这些患者的HBsAg和HBV DNA的水平。

研究结果如下:在215例患者中,113例(52.5%)感染的是基因A型HBV病毒,26例(12.0%)为基因B型,以及73例(34.0%)为基因C型。其中有21例(9.8%)发展为慢性感染,HBsAg持续时间长于6个月。基因A、B和C型HBV的转慢率分别为12.4%、3.8%和8.2%。在这21例患者中,只有6例(2.8%)未能在12个月内清除HBsAg,其中5例感染的是基因A型HBV病毒。

研究发现,12周时的HBsAg水平和4周时的HBVDNA水平对于区分出哪些患者将会发展为慢性感染是非常有用的。同样地,12周时的HBsAg水平和8周时的HBV DNA水平可用于区分哪些患者能在12个月内清除HBsAg。急性HBV感染后,HBV的清除发生在6-12个月内。只有那些无法在12个内清除HBV的患者才有可能最终发展为慢性感染。
High Levels of HBV after the Onset Lead to Chronic Infection in Patients with Acute Hepatitis B.
Abstract
Background. Some patients with acute HBV infection develop chronic infection. However, the method for identifying them has not been established. Methods. We followed 215 Japanese patients with acute HBV infection until the clearance of HBsAg or the development of chronic infection. Levels of HBsAg and HBV DNA were serially monitored from the onset. Results. Of the 215 patients, 113 (52.5%) possessed HBV genotype A, 26 (12.0%) genotype B, and 73 (34.0%) genotype C. Twenty-one of the 215 (9.8%) developed chronic infection, with the persistence of HBsAg for>6 months. The rate of chronicity of genotype A, B, and C was 12.4%, 3.8%, and 8.2%. Of the 21 patients, only six (2.8%) patients, including five with genotype A, failed to clear HBsAg within 12 months. Levels of HBsAg at 12 weeks and HBV DNA at 4 weeks were useful for distinguishing the patients who became chronic from those who did not (P <.001 and P<.001, respectively). Likewise, the levels of HBsAg at 12 weeks and HBV DNA at 8 weeks were useful for discriminating between the patients who lost HBsAg within 12 months and those who did not (P<.01 and P<.05, respectively). Conclusions. In acute HBV infection, clearance of HBV may happen between 6 and 12 months from the onset. Only those who fail to clear HBV within 12 months from the onset may really develop chronic infection.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1836576, encodeId=87e618365e6ef, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8524, encryptionId=f9d08524be, topicName=HBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Sat Feb 01 17:28:00 CST 2014, time=2014-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991549, encodeId=d6bf1991549e9, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Sun Jun 23 15:28:00 CST 2013, time=2013-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1694790, encodeId=a7781694e905e, content=<a href='/topic/show?id=c4df53524f3' target=_blank style='color:#2F92EE;'>#慢性感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53524, encryptionId=c4df53524f3, topicName=慢性感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6b229759322, createdName=wjywjy, createdTime=Mon Oct 07 03:28:00 CST 2013, time=2013-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1825580, encodeId=af4b182558062, content=<a href='/topic/show?id=1a942339426' target=_blank style='color:#2F92EE;'>#乙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23394, encryptionId=1a942339426, topicName=乙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Sat Apr 19 04:28:00 CST 2014, time=2014-04-19, status=1, ipAttribution=)]
    2014-02-01 klivis
  2. [GetPortalCommentsPageByObjectIdResponse(id=1836576, encodeId=87e618365e6ef, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8524, encryptionId=f9d08524be, topicName=HBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Sat Feb 01 17:28:00 CST 2014, time=2014-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991549, encodeId=d6bf1991549e9, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Sun Jun 23 15:28:00 CST 2013, time=2013-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1694790, encodeId=a7781694e905e, content=<a href='/topic/show?id=c4df53524f3' target=_blank style='color:#2F92EE;'>#慢性感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53524, encryptionId=c4df53524f3, topicName=慢性感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6b229759322, createdName=wjywjy, createdTime=Mon Oct 07 03:28:00 CST 2013, time=2013-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1825580, encodeId=af4b182558062, content=<a href='/topic/show?id=1a942339426' target=_blank style='color:#2F92EE;'>#乙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23394, encryptionId=1a942339426, topicName=乙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Sat Apr 19 04:28:00 CST 2014, time=2014-04-19, status=1, ipAttribution=)]
    2013-06-23 xlxchina
  3. [GetPortalCommentsPageByObjectIdResponse(id=1836576, encodeId=87e618365e6ef, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8524, encryptionId=f9d08524be, topicName=HBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Sat Feb 01 17:28:00 CST 2014, time=2014-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991549, encodeId=d6bf1991549e9, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Sun Jun 23 15:28:00 CST 2013, time=2013-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1694790, encodeId=a7781694e905e, content=<a href='/topic/show?id=c4df53524f3' target=_blank style='color:#2F92EE;'>#慢性感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53524, encryptionId=c4df53524f3, topicName=慢性感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6b229759322, createdName=wjywjy, createdTime=Mon Oct 07 03:28:00 CST 2013, time=2013-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1825580, encodeId=af4b182558062, content=<a href='/topic/show?id=1a942339426' target=_blank style='color:#2F92EE;'>#乙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23394, encryptionId=1a942339426, topicName=乙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Sat Apr 19 04:28:00 CST 2014, time=2014-04-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1836576, encodeId=87e618365e6ef, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8524, encryptionId=f9d08524be, topicName=HBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Sat Feb 01 17:28:00 CST 2014, time=2014-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991549, encodeId=d6bf1991549e9, content=<a href='/topic/show?id=f88a4e047f' target=_blank style='color:#2F92EE;'>#CID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4704, encryptionId=f88a4e047f, topicName=CID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=570f404, createdName=xlxchina, createdTime=Sun Jun 23 15:28:00 CST 2013, time=2013-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1694790, encodeId=a7781694e905e, content=<a href='/topic/show?id=c4df53524f3' target=_blank style='color:#2F92EE;'>#慢性感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53524, encryptionId=c4df53524f3, topicName=慢性感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6b229759322, createdName=wjywjy, createdTime=Mon Oct 07 03:28:00 CST 2013, time=2013-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1825580, encodeId=af4b182558062, content=<a href='/topic/show?id=1a942339426' target=_blank style='color:#2F92EE;'>#乙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23394, encryptionId=1a942339426, topicName=乙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Sat Apr 19 04:28:00 CST 2014, time=2014-04-19, status=1, ipAttribution=)]

相关资讯

EASL 2013:HBsAg临床应用的研究新进展

       本届欧洲肝脏研究学会(EASL)年会介绍了乙肝表面抗原(HBsAg)临床意义的研究进展,提示HBsAg作为HBV DNA的补充,在预测慢性HBV感染自然转归、抗病毒疗效、停药复发中有重要作用。但当前的研究大多样本量不足、随访时间偏短,将来仍需要更多的研究阐释HBsAg的临床价值。     &n

Gastroenterology:黑猩猩试验表明TLR-7口服激动剂GS-9620或可治疗慢性乙型肝炎

对于慢性乙型肝炎的治疗来说,直接抗病毒药物能够抑制乙型肝炎病毒(HBV)载量,但需终生服用。相比之下,刺激先天免疫系统能提高机体对病毒的控制能力,而且在有限的治疗之后获得长期效应。因此,来自美国德克萨斯州圣安东尼奥市德州生物医学研究所病毒学与免疫学部门的ROBERT E. LANFORD等人展开一项研究,研究结果于2013年2月14日在线发表于《胃肠病学》(Gastroenterology)杂志上

J HEPATOL:复旦大学闻玉梅院士等发现治疗性乙肝疫苗过度刺激可致疗效下降

尽管目前已报道了多种慢性乙型肝炎(CHB)感染的实验性治疗方法,但鲜有通过临床试验对这些方法进行确证。我国自主开发了一种以明矾为佐剂的治疗性乙肝疫苗(YIC),该疫苗由抗原-抗体(HBsAg[乙型肝炎病毒表面抗原]-HBIG[乙型肝炎免疫球蛋白])免疫原性复合物组成,旨在通过改变机体对乙型肝炎病毒(HBV)抗原的加工和呈递方式,从而消除免疫耐受。 先前已有研究报道了YIC的双盲安慰剂对照II B

EASL 2013:慢性乙型肝炎新近进展

第48届欧洲肝脏研究协会年会(EASL 2013 )于2013年4月24日至28日在荷兰—阿姆斯特丹 RAI会议中心隆重召开。年会内容涉及病毒性肝炎、自身免疫性肝炎、非酒精性脂肪性肝病、肝硬化、肝功能衰竭、肝癌及肝移植等。慢性乙型病毒性肝炎(CHB)研究相关进展HBV治疗新靶点  乙型肝炎病毒(HBV)感染宿主后在肝内形成共价闭合环状DNA(cccDNA), 无论是核苷(酸)类似物或是干

DDW 2013:NAFLD患者死亡危险因素仍然不明

      在2013消化疾病周(DDW)上公布的一项研究显示,非酒精性脂肪性肝病(NAFLD)患者的死亡因素包括老年、男性、躯干性肥胖和高密度脂蛋白胆固醇(HDL-C)水平低,换言之,与心血管疾病死亡和其他原因死亡的危险因素相同。另一方面,NAFLD患者的丙氨酸转氨酶(ALT)水平升高与死亡或其他不良结局风险增加无关,这意味着研究者需更

中国丙型肝炎流行病学状况与反思

       丙型肝炎是由HCV 感染而导致的一种传播途径明确、起病隐匿、慢性化程度高的疾病。HCV 感染呈全球性流行状态,是导致肝硬化和肝癌的最主要病因。最近世界卫生组织公布的数据表明,HCV 全球流行率为3% ,大约有1.7 亿人感染HCV 。而每年新发病例约3.5 万。   HCV 的感染率在不同国家、地区之间存在较大差异。世界范围内以埃及的流行

Baidu
map
Baidu
map
Baidu
map